Deletion of the G Protein-Coupled Receptor 30 Impairs Glucose Tolerance, Reduces Bone Growth, Increases Blood Pressure, and Eliminates Estradiol-Stimulated Insulin Release in Female Mice
Top Cited Papers
- 1 February 2009
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (2) , 687-698
- https://doi.org/10.1210/en.2008-0623
Abstract
In vitro studies suggest that the G protein-coupled receptor (GPR) 30 is a functional estrogen receptor. However, the physiological role of GPR30 in vivo is unknown, and it remains to be determined whether GPR30 is an estrogen receptor also in vivo. To this end, we studied the effects of disrupting the GPR30 gene in female and male mice. Female GPR30((-/-)) mice had hyperglycemia and impaired glucose tolerance, reduced body growth, increased blood pressure, and reduced serum IGF-I levels. The reduced growth correlated with a proportional decrease in skeletal development. The elevated blood pressure was associated with an increased vascular resistance manifested as an increased media to lumen ratio of the resistance arteries. The hyperglycemia and impaired glucose tolerance in vivo were associated with decreased insulin expression and release in vivo and in vitro in isolated pancreatic islets. GPR30 is expressed in islets, and GPR30 deletion abolished estradiol-stimulated insulin release both in vivo in ovariectomized adult mice and in vitro in isolated islets. Our findings show that GPR30 is important for several metabolic functions in female mice, including estradiol-stimulated insulin release. (Endocrinology 150: 687-698, 2009)Keywords
This publication has 48 references indexed in Scilit:
- Increasing Prevalence of the Metabolic Syndrome Among U.S. AdultsDiabetes Care, 2004
- Prevention of cancers of the breast, endometrium and ovaryOncogene, 2004
- Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone TrialDiabetologia, 2004
- Hormone Therapy: Physiological Complexity Belies Therapeutic SimplicityScience, 2004
- What pharmacologists can learn from recent advances in estrogen signallingPublished by Elsevier ,2003
- Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled TrialAnnals of Internal Medicine, 2003
- The Multifaceted Mechanisms of Estradiol and Estrogen Receptor SignalingJournal of Biological Chemistry, 2001
- Prevalence of Hypertension in the US Adult PopulationHypertension, 1995
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991
- LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGENThe Lancet, 1976